The “Ozempidemic” is not necessarily a bad thing, argues Wake Forest professor

The growing popularity of GLP-1 medications such as Ozempic is changing the conversations about weight loss and body image, with some describing widespread use of the drugs as an “Ozempidemic.” One Wake Forest psychology professor who researches GLP-1 medications, however, believes the online discourse about Ozempic oversimplifies the complex medical and social issues that surround obesity. “I understand why the term is catchy, but I think it can distract from the medical concerns that the drug is meant to treat,” Wayne Pratt said. “Obesity prevalence has risen dramatically over the last several decades, and obesity is associated with real risks for diabetes, cardiovascular disease and other health problems.” Originally developed to help manage type 2 diabetes, Ozempic’s active ingredient, semaglutide, has also become widely recognized for its ability to assist weight loss.

This excerpt comes from the named source. Read the original for the full reporting.